The encouraging pace of discovery and development in the field of regenerative medicine holds tremendous potential for bringing therapies to the clinic that may offer meaningful benefit to patients, particularly in diseases with no or suboptimal therapeutic options. Academic researchers will continue to play a critical role in developing concepts and therapies, thus determining whether regenerative medicine will be able to live up to this potential that clearly excites clinicians, researchers and patients alike. This review summarises recent developments in regulatory frameworks across different countries that aim to ensure adequate oversight of the development of regenerative medicine products, which are unique in structural and functional complexity when compared to traditional chemical drugs and fully characterised biological drugs. It discusses the implications of these developments for researchers aiming to make the challenging transition from laboratory to clinical development of these therapies and considers possible pragmatic solutions that could accelerate this process that is essential to maintain research credibility and ensure patient safety.
Introduction
Regenerative medicine has come to be a widely accepted term for the varied research efforts made in the last few decades to understand the basic science underlying regeneration of human tissue, organs and cells and translate this growing knowledge into potential therapeutic modalities for diseases hitherto not amenable to management or possible cure [1] . Stem cell therapies hold the potential to provide effective disease modification and possible cure for these diseases that have posed a tremendous challenge to clinicians and a heavy burden in terms of impaired quality and quantity of life for patients [2] . These diseases are associated with a burgeoning cost of suboptimal care for the community and the healthcare system. Successful regenerative medicine has the potential to address all these issues [3] .
Numerous stem cell therapies are currently in an exciting but critical clinical translational phase of development, as borne out by clinical trial registries across the world. It is interesting to observe that most ongoing research to date has initially been conducted in academic institutions. Industry has until recently, adopted a very cautious attitude in terms of involvement in development of these therapies [4] . Basic research is yet to provide broadly acceptable answers to key questions concerning structural and functional characterisation of different cell therapies. The challenges posed in terms of regulatory uncertainty and potential commercialisation models have meant that the key drivers in this field have been academic institutions and small to medium enterprises. Lack of experience in addressing regulatory requirements and limited financial and human resources often challenge such entities. As cell based therapeutics move into clinical translation phase, these issues assume critical significance as failure to address these efficiently can be a significant roadblock in procuring funding and approval for meaningful clinical studies critical to ensuring accelerated translation in this field [5] .
The inherent complexity of stem cell products and the still evolving understanding of the basic science underlying their mechanistic pathways of action pose a difficult challenge, especially when applied to chronic diseases where there is still an incomplete understanding of disease pathophysiology. The characterisation of chemical drugs has been relatively well understood, leading to advanced standardisation and regulation. However, the structural characterisation and mechanism of action for cellular products is poorly understood presently. Additional work around the validation and global standardisation of preclinical efficacy assays is needed, which makes these therapies not amenable to standard pharmacokinetic characterisation. This unfortunately makes the regulatory pathway difficult and unpredictable. These aspects create multiple challenges for scientists involved in the development of such therapies as they navigate their way through the complexity of development [6] .
In recent years, feedback sought from researchers in academia and industry concerning challenges in the development of regenerative medicine products has highlighted the lack of awareness and understanding of regulatory pathways as a significant deterrent to progress in this field [7] [8] [9] . This seems to be more prominent amongst academic researchers, which may potentially lead to the loss of many innovative developments in this field [7] [8] [9] . In light of the frantic pace of scientific advancement in molecular biology and its application in the area of regenerative medicine, it becomes even more critical that speedy, accurate and practical access to expertise in regulatory science is made available to academic researchers and clinicians, who are still the predominant drivers of translational research in the field of regenerative medicine. Recognition of this need for mechanisms for interdisciplinary collaboration is likely the first step towards accelerating the future pace of development of regenerative medicine.
In this review, we provide a concise description of key developments in regulatory pathways in regenerative medicine across the globe, aimed particularly at researchers in academic settings. This will enable expanded understanding of the key challenges faced in the development of regenerative medicine products and provide a summary of approaches initiated to address them.
Regulatory pathways in different jurisdictions

United States of America
The Food and Drug Administration (FDA) in the United States has been issuing guidance periodically for development of human cells, tissues, and cellular and tissue-based products (HCT/Ps) for clinical use utilising a tiered, risk-based approach [10] . The extent of FDA oversight required in the development process is dependent on two key considerations: the level of cell manipulation (minimal/more than minimal) and the intended use of cell therapy (homologous/non-homologous) [11] . An HCT/P is regulated under section 361 of the Public Health Service Act 1944, which entails an abbreviated review, if it is minimally manipulated, is intended for homologous use only and does not involve the combination of the cells or tissues with other materials, which may raise new clinical safety concerns. The products that undergo more than minimal manipulation and/or are used in a non-homologous manner are deemed 'biological products' (Fig. 1) . These undergo an extensive development process with the approval of clinical trials in humans requiring compilation of pre-clinical evidence, the submission of an Investigational New Drug Application (IND) and the submission of a Biologics License Application (BLA) under section 351(i) of the Public Health Service Act 1944 and related regulations.
The FDA issued 'Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products' in 2015 [12] providing recommendations for clinical translation of HCT/Ps that fulfil the criteria for being a biological drug product, thereby requiring regulatory oversight under section 351 (Table 1) . These recommendations pragmatically acknowledge the fact that the distinctive characteristics and feasibility challenges with these products influence the design considerations of early-phase clinical trials of HCT/Ps. The recommendations also acknowledge the limitations in the extrapolation of pre-clinical data to inform early phase study design especially in context of highly humanised or species-specific cell based products. In addition, the FDA developed recommendations for preclinical assessment of cell therapy products, which reflect the authority's openness to move beyond the established pre-clinical guidance based on small molecule therapies, supported by reasonable and scientifically sound evidence [13] .
These recommendations lay particular emphasis on the characteristics of cell therapy products such as their ability to express molecules and factors that affect and are in turn, affected by the local microenvironment, and their ability to migrate and differentiate in vivo into undesired cell types. In addition, the impact of potential viral vector contamination and any adventitious therapy/intervention (e.g. immunosuppression/invasive procedures/combination therapies) needs to be evaluated in detail to ensure the safety of potential research participants in clinical trials.
The FDA recognises that the challenges with manufacturing these products may determine feasible doses and emphasises potential issues with the variability within different lots of the products. The guidance underscores the importance of establishing and maintaining GMP standards early in development of the product.
Whilst the principal intent of early phase trials is the assessment of safety and feasibility, as most cell therapy products are likely to be investigated in disease populations to justify the risk inherent in these therapies, the recommendations encourage preliminary assessment of efficacy and obtaining 'proof of concept' data in humans in early phase trials to better inform further development. To that end, activity assessments in the trial design are required to be detailed and justified in the context of the given disease indication and cell therapy product.
The FDA guidance on Good Tissue Practice (GTP) requirements for cell therapies provides safeguards to minimise the risk of communicable disease transmission by HCT/Ps and prevent contamination during manufacturing [14] . Depending on whether the product is autologous or allogeneic, additional requirements such as donor screening may also be applicable.
European Union (EU)
In Europe, cell therapies are evaluated under Advanced Therapy Medicinal Products (ATMP), which include three major types of products specifically, gene therapy, somatic cell therapy and tissue engineered products, as set out in [15, 16] . These regulations lay down additional scientific and technical requirements regarding the testing of ATMPs for human use. The regulations deem that these therapies be considered as drugs if they are intended for non-homologous use and have undergone substantial manipulation. In this case, the relevant guidelines for development of biological therapies will be applicable (Fig. 2) . The European Medicines Agency (EMA) recognises that evaluation of ATMPs requires specific expertise and has set up a Committee for Advanced Therapies (CAT) to evaluate the quality, safety and efficacy of each ATMP. The CAT acknowledged that studies for generating quality and nonclinical safety data for ATMPs are often conducted either by small and medium-sized enterprises or in academic institutions [17] . The EMA framework proposes a system of evaluation and certification wherein the CAT, independent of any marketing authorisation application, can evaluate the data from such studies. It also evaluates the implementation of Good Clinical Practice (GCP) and/or Good Laboratory Practice (GLP) in these studies, which may facilitate future application for clinical trials and marketing authorisation application based on the same data.
The EU regulatory pathway recognises the need to incorporate flexibility in evaluation of the manufacturing of these products in light of the specific technical characteristics of advanced therapy medicinal products [18] . Thus, whilst decreeing that the manufacture of advanced therapy medicinal products should be in compliance with the general principles of Good Manufacturing Practice (Commission Directive 2003/94/EC) [19] , there are recommendations to develop guidelines specific to ATMPs to accurately reflect the specific challenges in their manufacturing process.
Japan
Japan's new regenerative medicine legislations aimed at accelerating the development of regenerative medicine products came into force in November 2014 (Fig. 3) . The Pharmaceutical, Medical Devices and Other Therapeutics (PMD) Act 2014 will regulate the commercial development of regenerative therapeutics [20] . The act lays down provisions for accelerated approval, contingent on provision of early safety and indicative evidence of therapeutic benefit of an investigational therapy studied in well-designed Phase 1/2 trials, after review by the Office of Cellular and Tissue based Products within Pharmaceutical and Medical Devices Agency (PMDA) [21] . The seven-year period following conditional approval entails mandatory capture and provision of in-clinic data on efficacy and safety through defined mechanisms. By the end of this period, the sponsor either applies for final marketing approval (the equivalent of a Biologic License Application [BLA] in the US) or withdraws the product.
In addition, the Act on the Safety of Regenerative Medicine 2014 (ASRM) defines the pathway to oversee the cell therapies administered in medical practice using processed cells and in the context of academic clinical research [22] . The law has enabled a pathway of oversight that involves a tier-based, risk-dependent analysis and enables accreditation of cell processing centres for safer and resource efficient manufacturing. The institution that provides the cell therapy has to report annually on safety evaluation and scientific acceptability of these products to the Committee for Regenerative Medicine and Ministry of Health, Labour and Welfare.
Canada
The Biologics and Genetic Therapies Directorate, Health Canada, provides regulatory oversight for the clinical development of regenerative medicine products (Fig. 4) as stipulated mainly by the Food and Drug Act 1985 [23] , Safety of Human Cells, Tissues and Organs for Transplantation Regulations 2007(CTO Regulations) [24] and the Guidance document -Safety of Human Cells, Tissues and Organs for Transplantation Regulations 2013 [25] . The CTO Regulations currently regulate minimally manipulated cell and tissue products that are intended for allogeneic and homologous use only.
Health Canada reviews the conduct of clinical trials investigating the use of these products in human subjects. It also issued a 'Guidance document for Preparation of Clinical Trial Applications for use of Cell Therapy Products in Humans' in 2015 [26] , that emphasised the need for appropriate characterisation and adherence to GMP requirements early in development and highlighted the need for proactive discussion to address ambiguity in this regard. Institutional human research ethics boards review clinical research in accordance with the 'Tri-Council Policy Statement (TCPS): Ethical Conduct for Research Involving Humans', as well as other local and international guidelines. In 2014, the TCPS was amended to incorporate the 'Guidelines for Human Pluripotent Stem Cell Research' formulated by the Canadian Institute of Health Research (CIHR), which requires approval by a Stem Cell Oversight Committee for research activity funded by one of the national research funding agencies [27] .
Australia
In Australia, cellular therapy products are regulated under the 'Australian Regulatory Guidelines for Biologicals' released by the Therapeutic Goods Administration (TGA) in 2014 [28] (Fig. 5) . 'The National Statement on Ethical Conduct in Human Research 2007' updated in 2015 provides guidance for clinical research undertaken in Australia [29] . The Prohibition of Human Cloning for Reproduction and the Regulation of Human Embryo Research Amendment Act 2006 [30] , place further stipulations specific to research with embryonic stem cells. Whilst materials used in initial clinical research may be exempted from requirements for GMP, the TGA requires that investigational products used for phase 2 and 3 clinical trials meet GMP requirements [31] .
Clinical Trial Notification or Exemption pathways (CTN/CTX) enable access to investigational products in the context of clinical trials [32] . Whilst CTN entails only a notification to the TGA, CTX mandates a complete review by the TGA before a trial can commence. The sponsors of the trials (either academic or industry) determine, in consultation with institutional human ethics review committees (HERCs) and relevant authorities, the most appropriate pathway dependant on the understanding of risk involved with a given investigational therapy. The primary accountability for oversight of research activities still vests with the relevant institutional authority and HERCs.
In the context of cell therapies, HERCs often may not have sufficient local expertise to review such research proposals. Bodies such as the Advisory Committee on Biologicals (ACB) and the Gene and Related Therapies Research Advisory Panel (GTRAP) are available to provide such expertise.
The autologous use of stem cell therapies, in the context of provision of a single course of treatment with self-donated cells provided or manufactured under the supervision of a medical practitioner who has the overall 'management of care' responsibility for the patient, is not regulated by the TGA as specified in the Therapeutic Goods (Excluded Goods) Order [33] . The Medical Board of Australia and the Australian Health Practitioner Regulation Agency (AHPRA) in accordance with the Health Practitioner Regulation National Law, 2009, currently regulate provision of such therapeutic options under 'innovative clinical practice'. In 2015, the TGA released a discussion paper with possible options for regulation of such cell therapies that range from continuation of the current pathway to a complete oversight by the TGA, as implemented in context of other biological drugs [34] . The discussion paper sought to obtain public opinion on the need to create a framework for regulating autologous stem cell therapies, some of which are provided in private non-academic and for profit stem cell clinics in Australia at substantial costs to the patient, with limited scientific basis and usually without preclinical safety or efficacy studies.
The lack of a clearly defined pathway for use of either autologous or allogeneic stem cells use in humans within federal legislation framework in Australia presents a confusing situation for investigators. Unfortunately, this uncertainty has the impact of slowing progress in regenerative medicine research in Australia. It also provides an opportunity for non-scientific use of stem cells in clinical practice in Australia, which can be detrimental for patients and this young field's reputation.
3. Challenges for academic research -considerations for the future 3.1. Harmonisation across different regulatory bodies: challenges in standardisation of terminology Whilst the individual regulatory bodies around the world are continually evolving their oversight frameworks, certain common themes are emerging across the different regulatory environments, which may be the starting point for future harmonisation. Such efforts for convergence, if successful, would be key contributors to future acceleration in the translation of advanced cell/gene therapies to the clinic.
The definitions of key attributes in cellular therapies such as 'minimal manipulation' and 'homologous/non-homologous use' have hitherto varied in scope across different jurisdictions. Whilst different agencies, notably FDA and EMA, are clarifying these terms [18, 35] , there is need for convergence of these definitions across regulatory jurisdictions. This could prove a significant enabler for the success of multinational research collaborations that are critically required at this stage of translation with most cell therapies. This is borne out by the fact that sharing of expertise and new knowledge being generated is cited by most stakeholders as the need of the hour [36, 37] . However, practical success in this direction can only be made if operational uncertainties due to divergent regulatory environments can be decreased, thereby creating opportunities for researchers to collaborate across the globe.
At present, a significant proportion of cell therapy products under investigation represent heterogeneous populations of cells rather than a high purity single population of cells. Given the unique attributes of these therapies that make them straddle the boundaries between biological drugs and surgical/transplantation products, developers will certainly benefit from working together and learning from experts through practical examples and innovative approaches towards characterisation and standardisation. Establishment of such research networks can also increase the commercial attractiveness of these therapies, potentially increasing the much-needed investment from industry. The majority of product development research involving cell therapies is occurring in academic centres involving scientists and clinicians. These academic researchers often lack the technical, financial and human resources to navigate the necessary but complex regulatory process required for clinical translation of these therapies.
In the last few years, studies from the US, Canada and UK have reported on the level of awareness and understanding of the existing regulatory framework as applicable to regenerative medicine amongst clinician scientists and academic researchers [7, 8] . These studies have indicated consistently that whilst there is an elementary awareness of possible regulatory requirements, most academic research teams find the current regulatory pathways difficult to understand and implement in their development projects. This clearly can pose significant challenges to clinical translation and eventual commercialisation.
Researchers, whilst accepting the importance of regulations to ensure safety and quality of regenerative medicine products, have indicated a need for modifying the product testing and quality requirements applicable to cell therapies. The complexity in the application of often difficult to understand regulatory requirements, the ambiguity regarding the level and extent of evidence needed regarding effectiveness and safety and the classification of investigational products is often overwhelming for academic research teams. These teams usually lack the regulatory and quality control and assurance expertise available in industry. The enthusiasm to advance these therapies that potentially hold significant benefit for patients has seen researchers move into clinical trials with less than complete understanding of the biology of the therapy with attendant implications for safety. However, an important factor with cell therapies is the fact that their duration of action is potentially life long and irreversible. In this context, it is imperative to create global networks for knowledge sharing that may enable research teams to complement each other towards a more comprehensive understanding of different cell types in terms of their molecular and functional characterisation. This would provide critical opportunities to avoid repetition of negative experimentation. Creation of research consortiums focused on particular stem cell types similar to the disease specific research networks that currently exist could potentially enable interand cross-disciplinary exchange to address components of the development process that are common within and across the varied disease indications in which clinical application is investigated. This is likely to increase the efficiency and success of researchers in this field tremendously. However, for this to be a practical reality, government, legal and regulatory structures have to evolve pragmatically to create these platforms for academic or industry-led research whilst ensuring protection of intellectual property and the ability to publish innovative findings in high impact journals.
Importantly, we propose that basic scientists and clinical research teams should be actively supported to seek access to their local regulatory agencies early in the development of potentially new regenerative medicine therapies. The documents cited in this review provide starting points for future dialogue. Most regulatory agencies are very willing to speak with academic research groups. Whilst it has been possible to administer investigational product that was manufactured without demonstration of GMP compliance in Phase 1 studies, it is critical for researchers to understand that they will be unable to move beyond Phase 1 without transition to GMP compliance, a step that can prove expensive in terms of time and money.
With respect to the preparation of stem cells for human use, it is also important for research teams to understand the importance of xenogeneic agent exposure. Whilst there are ways to include certified sources of foetal calf serum in manufacturing processes, there are other important issues. For example, murine sourced monoclonal antibodies used in cell selection may be a significant problem.
Regulatory agencies can facilitate the transition to clinical trials for academic and clinical researchers by establishing single point contacts for advice and providing this information on their websites. The regulatory agencies have been participating in information sessions on basic regulatory and safety requirements at clinical and research meetings. However, given the complexities of regenerative medicine products, a system that enables early, product-specific dialogue that could start at the beginning of product development, could go a long way in building regulatory competence amongst developers, especially those from the academia.
Access to expertise in manufacturing
Stakeholders in this field agree on the need for established technical standards, in terms of quality, safety and efficacy, through demonstrated adherence to GLP, GMP and GCP whilst conducting research through pre-clinical and clinical phases [38] . Having said that, the challenges in establishing appropriate quality standards are underscored by the fact that most agencies have committed to developing guidance specific to advanced medical therapies. The Important to collect data on characteristics of the administered product and clinical outcomes to enable correlative analyses to help in dose definition. Repeated dosing might not be an acceptable risk in most studies until availability of preliminary data on the product's toxicity and duration of activity. Treatment plan Staggered administration within a cohort or between cohorts-the staggering interval should be long enough to monitor for adverse events prior to treating additional subjects at the same/increasing dose. Cohort size determined by safety considerations and manufacturing capacity Failure-to-treat may be an important trial endpoint as part of a feasibility evaluation; plans to analyse the proportion of failure to-treat subjects to look for factors that may predict failure to administer the product and to evaluate the consequences to the subject if there is a failure to treat.
Monitoring and follow-up
Assessments targeting specific safety issues that could be anticipated with these products; pre-defined study -stopping rules. Duration of follow-up period in which the product might reasonably be thought to present safety concerns should be justified.
unique and incompletely characterised structural and functional attributes of these therapies are challenging for regulators and developers alike, especially when they are more familiar with fully characterised chemical and biological drugs, rather than living cells. This is clearly an area of regulatory science, that needs to expand exponentially and interactively to keep pace with scientific progress in product discovery [39] . Research to identify key functional characteristics and possible biomarkers of efficacy, potency and safety risks such as tumorigenicity and unwanted biological effects requires long-term support, probably best done through institutions with basic science and commercialization expertise. Regulatory agencies can potentially facilitate widespread access to the findings of such research by exploring pragmatic ways to share those aspects, which have generic significance to these therapies whilst protecting intellectual property. This may contribute to translational success and ensure safety of the patients participating in clinical trials [40] . Ensuring GMP compliant manufacturing of cell therapies for the clinical phase of development is perhaps the biggest challenge for academic research teams seeking to translate their research clinically. The complexity of the cellular products often results in product characterisation and associated assays and standards being developed at the same time as the product itself.
On the other hand, the regulatory reviewers are themselves at a stage of learning about the application of existing GMP requirements, the body of evidence that is needed in the context of a given product and what is practically feasible in light of the current stage of technology. This understandably protracts the decision making process and adds to the time and money required. The move from a small-scale laboratory to clinical grade production of investigational product is daunting, especially for investigators from academic institutions, predominantly due to lack of funding and access to expertise in regulatory science and manufacturing. The National Heart Lung and Blood Institute (NHLBI), National Institutes of Health (NIH) has led the way to address this issue by establishing the Production Assistance for Cellular Therapies (PACT) program in 2003 which provides (i) clinical product manufacturing support for phase 1 and 2 trials and (ii) translational development support, to enable the translation of laboratory-based techniques into GMP compliant production methods and Standard Operating Procedures (SOPs) for investigator initiated projects [41] . The fact that PACT has been able to support numerous projects with encouraging success and the present remit of its manufacturing support being limited to treatment of heart, lung, and blood diseases, begs for similar programs to be developed for diseases involving other organs (e.g. the brain) with significant disease burden such as stroke and neurodegenerative disorders. The CellCAN network, another promising example, was started in 2009 in Canada and incorporated as a not-for-profit corporation in 2014. The CellCAN presents a potentially replicable model of a national enterprise comprising different stakeholders such as academic researchers with demonstrated interest in the field, industry, clinicians, funding bodies and regulatory bodies [42] . The network aligns the requirements for manufacturing facilities with expertise in processing cell products for clinical trials to ensure capacity, scalability and quality management processes to ensure efficient trial execution.
In 2016, EMA launched PRIME scheme [43] to enable early proactive regulatory dialogue between the applicant and the EU regulatory network regarding the development plan of therapies of 'major public health interest' and which represent significant innovation, through ongoing advice from relevant stakeholders. Whilst sponsors can apply to be considered for PRIME based on preliminary clinical evidence (proof of concept), EMA has expressed openness to provide exceptional earlier access to academia and small to medium enterprises if there is compelling nonclinical data (proof of principle) in a relevant model and first in human studies indicate adequate period of exposure for preliminary pharmacological and tolerability data.
Mechanisms for accelerated access: implications for cell therapies
The regulatory bodies across the world have developed different mechanisms for providing accelerated access to therapies, particularly in disease indications with current unmet need.
The FDA has put into place a number of potential pathways to decrease the time to market availability of therapies that serve clear unmet needs such as Fast Track Approval [44] , Breakthrough Therapy Designation [45] , Priority Review and Accelerated Approval [46] . The Fast Track process is aimed to expedite the review and in-clinic availability of investigational biological drugs and cell products for medical conditions with present unmet needs. Accelerated Approval allows for expedited review and approval based on data related to scientifically valid surrogate endpoints instead of established clinical endpoints. Breakthrough Therapy designation is the newest mechanism that is used if existing preliminary data on a therapy indicates substantial improvement in outcomes in a disease indication with an unsatisfactory therapeutic status quo. A number of cell-based therapies are currently being reviewed under the Fast Track Approval process.
An interesting development is the passage of 'right to try' (RTT) laws in certain states in the US. The RTT can potentially be pursued for individual 'gravely ill' patients for access to cell therapy products ahead of FDA-approval. The practical utility of these laws, however, has already been questioned as they are contrary to current federal legislations and may draw resources away from efforts to develop effective treatments and may further complicate the FDA pathway for compassionate use of medications [47] . This also raises concerns in that some stem cell clinics are already willing to provide inadequately tested stem cell therapies utilizing the current gap in the capability of the FDA to ensure adequate regulation.
The EMA issued a 'Guideline On Compassionate Use of Medicinal Products' in 2006 which allows for access to potentially beneficial therapy to a group of patients ahead of regulatory approval but left its implementation to individual EU member states [48] . The European Commission introduced the 'hospital exemption clause' by the Regulation (EC) No.1394/2007 [49] for ATMPs that is applicable to those ATMPs that are prepared on a non-routine basis, i.e. individually prescribed, according to specific quality standards, for an individual patient. These therapies are provided in a hospital under the exclusive professional responsibility of a medical practitioner within the EU. This provides a mechanism to provide individual patient-centred care in relevant clinical situations, whilst ensuring product quality and patient safety (through the requirement of a system for patient and product traceability).
Dilemma named 'innovative medical practice'
Growth of stem cell therapies, in particular autologous therapies, has brought forth an important issue that has defied consistent definition for many years [50] . The boundaries between research and innovative medical practice are being re-examined in the wake of an explosion in 'stem cell clinics' offering various cellular therapies in routine practice. Most of this activity involves the use of autologous fat-derived stem cells with little or no supporting basic scientific preclinical data. Provision of cell therapies under the guise of 'innovative medical practice' may encourage widespread adoption of therapies that may be ineffective at best and harmful at worst. Academic researchers are understandably very concerned with these practices, which can serve as a significant disincentive and message to the lay public that fundamental research is not required. Thus, these practices can challenge future scientific translational success in this field. Even now, the provision of cell therapies in such clinics is largely self-regulated in most parts of the world. Medical practitioners' regulatory authorities in different countries, variably regulate this practice and lack adequate legislative, financial or skilled human resources to provide effective oversight for practice involving this fast advancing field [51] .
The stem cell industry has burgeoned not only in the developing regions such as Mexico, China, India and south-east Asia but also in developed countries such as the US, Germany and Australia [36, [52] [53] [54] [55] . A recent report by Turner et al. indicates approximately 351 distinct ventures providing commercial cell therapy interventions at 570 centres across the US for a range of diseases [56] . This is a significant reflection on the limited success of the initiatives of the FDA, in recent years, towards increased involvement and the clear struggle for effective oversight of a fast expanding field. Berger et al. present an interesting perspective that the stem cell industry is a significant presence across the globe and not restricted to countries with poorly defined regulatory pathways [56] . In addition, an important consideration may also be that developed countries such as the US and Australia have higher numbers of clinics per capita, highlighting the ease with which access to such therapies is possible in these countries [57] . There is a formidable risk for patient safety, due to rampant lack of clarity on source and quality of cell therapies being administered at these sites. The aggressive and often misleading marketing of these therapies results in patients undergoing interventions with questionable safety and effectiveness [56] .
Whilst the negative impact on patient safety is evident and increasingly being highlighted, the implications for research success have perhaps not garnered as much attention [56, 57] . On the one hand, patients undergoing such interventions become unavailable or ineligible for bona-fide clinical research, which increases recruitment challenges and cost of research. On the other hand, the discredit resulting from adverse safety incidents in recipients of these services, severely undermines the confidence in the future potential for this research field. This has both immediate and far reaching impact on attractiveness of this research area for potential funding and investment in clinical translation from government and industry alike as well as the interest amongst academics to pursue research in this clearly emotive and polarised field. Clearly, this presents a cause for concern for all stakeholders in regenerative medicine and poses significant threat to future translational success in regenerative medicine.
A pragmatic attempt to address this issue, which, if successful, may provide a way forward, would be the establishment of a dedicated pathway for the oversight of research as well as routine medical practice. Japan has been highly progressive in this respect enacting the Act on the Safety of Regenerative Medicine that came into effect in 2014 and aims to provide oversight of provision of cell therapies in medical practice [21] . This pathway enables medical institutions to outsource cell culturing and processing to industry/centres with the required expertise and accreditation under a much more streamlined process and mandates collection of necessary safety and efficacy data.
Conclusions
Regulation and innovation in clinical translation are closely linked and determine the success of commercialization of scientific discoveries. Changes in regulatory frameworks, often driven by scientific advances, can potentially enable or hinder innovation. Advancing regulatory policy and creating modalities for widespread access to this expertise, especially for academic research communities, will ensure robust interdisciplinary collaboration and foster shared learning critical to successful translation. As observed in different countries throughout the world, an environment of facilitative legislation is crucial. The hypothesis is that regenerative medicine may result in a paradigm shift in clinical medicine, not seen since the introduction of antibiotics. These therapies, if successfully translated into clinical practice, may provide meaningful options to society, currently reeling under the burden of diseases that take a substantial toll on lives of so many across the globe.
